Octreotide in the treatment of severe chemotherapy-induced diarrhea

Annals of Oncology

Volumn 12, Issue 2, 2001, Pages 227-229

  Zidan, J ^a,b   Haim, N ^b,c   Beny, A ^b,c   Stein, M ^b,c   Gez, E ^b,c   Kuten, A ^b,c  

^a Rebecca Sieff Government Hospital   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Octreotide; Refractory chemotherapy induced diarrhea; Treatment

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; METHOTREXATE; OCTREOTIDE; OPIATE;

ADULT; AGE; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENDER; HOSPITALIZATION; HUMAN; MALE; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SIDE EFFECT; STOMACH CANCER; TIME; TUMOR LOCALIZATION;

ADULT; AGED; ANTIDIARRHEALS; ANTINEOPLASTIC AGENTS; DIARRHEA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OCTREOTIDE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035104754     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008372228462     Document Type: Article

References (19)

1. Recommended guidelines for the treatment of chemotherapy-induced diarrhea
2. The modulation fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial
3. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer
4. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma
5. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
6. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
7. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study
8. Drug therapy for diarrheal diseases: A look ahead
9. Control of chemotherapy induced diarrhea with octreotide in patients receiving 5-fluorouracil
10. Bowel rest, intravenous hydration and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy induced diarrhea in patients with colorectal carcinoma
11. Necrotizing colitis in patients with cancer
12. Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats
13. Constipation and diarrhea in cancer patients
14. Effect of somatostatin analogue Sandostatin (SMS 201-995) on gastrointestinal, pancreatic, and biliary function and hormone release in normal men
15. Effect of somatostatin analogue on water and electrolyte transport and transit time in human small bowel
16. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: A randomized trial
17. Octreotide acetate in refractory bone marrow transplant-associated diarrhea
18. Sandostatin (S) therapy for chemotherapy (CT) and radiotherapy (RT) related diarrhea (D)
19. Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea